leadf
logo-loader
viewAIM ImmunoTech Inc

AIM Immunotech forms Phase 1/2a clinical trial agreement to fight the coronavirus

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that it has struck a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support its Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with the coronavirus.

What's more, Equels says the group has reached an agreement with Japan’s National Institute of Infectious Diseases and pharmaceutical company Shionogi & Co Ltd to test its drug Ampligen as a vaccine enhancer for the coronavirus.

Quick facts: AIM ImmunoTech Inc

Price: 2.27 USD

NYSE:AIM
Market: NYSE
Market Cap: $90.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to...

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China. Equels telling Proactive how this drug will try to be a...

on 3/3/20

2 min read